Edwards Lifesciences (NYSE:EW) Hits New 1-Year High – Time to Buy?

Edwards Lifesciences Corporation (NYSE:EW) shares hit a new 52-week high on Friday . The stock traded as high as $89.48 and last traded at $86.2030, with a volume of 1470859 shares traded. The stock had previously closed at $87.45.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EW. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. BTIG Research upped their target price on Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a report on Wednesday, April 1st. Robert W. Baird boosted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Finally, Evercore restated an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $95.96.

Edwards Lifesciences Price Performance

The company has a market cap of $49.59 billion, a PE ratio of 45.84, a PEG ratio of 2.16 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock’s 50-day moving average is $82.15 and its 200 day moving average is $83.04.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period in the previous year, the company earned $0.64 earnings per share. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the sale, the vice president directly owned 33,934 shares in the company, valued at approximately $2,747,975.32. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 95,057 shares of company stock valued at $7,874,217 in the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Large investors have recently bought and sold shares of the stock. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $266,000. NewEdge Advisors LLC increased its position in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after acquiring an additional 2,665 shares during the period. Sei Investments Co. increased its position in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after acquiring an additional 58,988 shares during the period. Squarepoint Ops LLC increased its position in shares of Edwards Lifesciences by 277.7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after acquiring an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina increased its position in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after acquiring an additional 1,065 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.